The levels of ACIVAbs IgM were significantly lower in the T2D group compared to healthy controls (0.12 ± 0.06 vs. 0.18 ± 0.09; p = 0.016; Figure 1A). This evidence concerns the gene CD40LG and type 2 diabetes mellitus.